Recent developments include Roth Capital initiating coverage of Nuo Therapeutics with a buy recommendation in December 2025 and historical news of the company withdrawing an $11 million IPO attempt in 2017.

• Roth Capital initiated coverage of Nuo Therapeutics with a buy recommendation in December 2025 [N1].
• Nuo Therapeutics withdrew an $11 million US IPO in August 2017 [N2].

The Aurix System's FDA clearance and Medicare coverage provide a foundation for commercial adoption in the chronic wound care market, which addresses significant unmet medical needs. The company has demonstrated revenue growth from initial commercialization efforts and has established a distribution partnership with Smith+Nephew, potentially expanding market reach. Clinical evidence supports the efficacy of Aurix in promoting wound healing, which may drive increased physician adoption. The company’s focused commercial strategy and expanding sales network could support further revenue growth and improved market penetration.

Nuo Therapeutics has a limited operating history since restarting commercialization and has incurred consistent net losses, raising concerns about its ability to achieve profitability. The company’s liquidity position is constrained, with limited cash reserves and a current ratio near parity, indicating potential funding challenges. Competition from larger companies with more resources and established products may limit market share growth. The exclusive distribution agreement with Smith+Nephew for a private label product may also create internal competition and limit the company’s own branded product sales. Regulatory and reimbursement risks remain, including dependence on Medicare coverage and local contractor decisions. The company’s small employee base and limited resources may constrain operational execution and growth.

Nuo Therapeutics' moat is based on its FDA-cleared Aurix System, which is one of only three platelet derived products cleared for chronic wound care. The product's autologous approach leverages the patient's own blood to deliver biologically active growth factors that promote healing, supported by published clinical studies. The company benefits from Medicare coverage established through a National Coverage Determination, enabling reimbursement that supports commercial viability. Its distribution agreement with Smith+Nephew provides access to a large sales network and market reach in the U.S. However, the company faces competition from larger, better-resourced firms and must continue to expand physician awareness and reimbursement coverage to maintain and grow market share. Intellectual property protections include trademarks and trade secrets but the product competes in a market with multiple alternative therapies and established habitual use patterns.

• Financial Position and Liquidity: The company has a history of net losses and limited cash resources, raising substantial doubt about its ability to continue as a going concern without additional financing.
• Market Adoption and Competition: Aurix faces competition from other FDA-cleared platelet derived products and advanced wound care therapies from larger companies with greater capital and marketing resources.
• Dependence on Medicare Coverage: Commercial viability depends on Medicare reimbursement policies, which could change or be inconsistently administered by local Medicare Administrative Contractors.
• Distribution Agreement Risks: The exclusive distribution agreement with Smith+Nephew for a private label product may limit the company’s ability to expand its own branded product sales and create internal competition.
• Regulatory and Compliance Risks: The company’s products and operations are subject to extensive regulation; failure to comply could result in penalties, product recalls, or suspension of operations.
• Operational Constraints: Limited number of employees and resources may affect the company’s ability to effectively conduct operations, expand sales networks, and support customers.

• Nuo Therapeutics, Inc. is a Delaware corporation originally organized in 1998 and has undergone several name changes and bankruptcy reorganizations, most recently emerging from Chapter 11 in 2016 [S1].
• The company is a commercial-stage medical device company focused on developing and marketing products for chronic wound care primarily in the U.S. [S1].
• Its principal commercial product is the Aurix System, an FDA 510(k) cleared device since 2007 that produces autologous platelet rich plasma (PRP) gel for wound management, including chronic wounds such as diabetic foot ulcers, leg ulcers, and pressure ulcers [S1].
• Aurix is one of three FDA-cleared platelet derived products for chronic wound care and competes in an advanced wound care market estimated at $10.8 billion globally in 2021 [S1].
• The Aurix System uses the patient's own blood to produce a biologically active hematogel that delivers growth factors and signaling molecules to promote wound healing [S1].
• The company restarted business activities in October 2021 following a favorable CMS National Coverage Determination (NCD) in April 2021 that established Medicare coverage for autologous PRP products [S1].
• Commercially available Aurix product became available for demonstration and evaluation in May 2022, with product revenues increasing from approximately $1.4 million in 2024 to approximately $3.1 million in 2025 [S1].
• As of December 31, 2025, Nuo Therapeutics had contractual relationships with over 200 third-party sales agents and distributors [S1].
• In March 2025, the company entered a Distribution Agreement with Smith+Nephew for exclusive U.S. distribution of a private label Aurix product, with minimum annual purchase commitments averaging $500,000 per year during the initial term [S1].
• Smith+Nephew paid an upfront distribution fee of $1.5 million and may pay up to an additional $750,000 based on reimbursement milestones; these fees are refundable pro rata if terms are not met [S1].
• The Distribution Agreement is initially for five years, renewable for two-year terms, and allows Nuo to continue marketing its own Aurix branded product alongside the private label product [S1].
• The company relies on trademarks, trade secrets, copyrights, confidentiality agreements, and contractual provisions to protect its intellectual property [S1].
• Nuo Therapeutics faces competition from other FDA-cleared platelet derived products and from pharmaceutical, biopharmaceutical, and medical device companies offering advanced wound care dressings, devices, and biologics [S1].
• The company had a net loss of approximately $2.5 million for the year ended December 31, 2025, and reported basic EPS of -$0.05 for the same period [S1].
• As of December 31, 2025, the company had cash and cash equivalents of approximately $549,000 and a current ratio of 1.06, indicating near parity of current assets to current liabilities [S1].
• Nuo Therapeutics had 10 full-time employees as of December 31, 2025, all salaried, with no union representation [S1].
• The company ceased standard operations in May 2019 pending CMS reconsideration and resumed activities after the 2021 CMS NCD [S1].
• The Aurix System's Medicare reimbursement rates for 2026 are $2,108 per treatment in hospital outpatient departments (POS 22) and $1,064 per treatment in private physician offices (POS 11) [S1].
• The company’s commercial strategy focuses on increasing physician awareness and expanding distributor and sales agent networks primarily in the U.S. [S1].
• Nuo Therapeutics has a history of financial losses and limited operating history since restarting commercialization in 2022, with risks related to liquidity and the need for additional financing [S1].
• The company’s revenues derive primarily from sales of Aurix and the private label product to hospital outpatient clinics and private practice physicians [S1].
• There are no material pending legal claims against the company as of the latest filings [S1].
• The company’s products and operations are subject to extensive regulation by U.S. and international authorities, including FDA and CMS [S1].
• The company’s Distribution Agreement with Smith+Nephew includes exclusivity for the private label product in the U.S., but Nuo retains rights to market its own branded Aurix product [S1].
• The advanced wound care market includes established competitors with greater capital and marketing resources, posing competitive challenges [S1].
• The company’s liquidity ratios as of December 31, 2025, include a cash ratio of 0.42 and a current ratio of 1.06, reflecting limited liquidity [S1].
• The company’s recent news includes Roth Capital initiating coverage with a buy recommendation in December 2025 [N1].
• Historical news includes the withdrawal of an $11 million IPO attempt in 2017 [N2].